logo-loader

Morning Report: City watchdog probing Barclays CEO links to sex offender Epstein

Headlines from the Proactive UK newsroom.

Barclays (LON:BARC) says it remains confident in the ongoing leadership of chief executive Jes Staley while the City watchdog carries out an investigation into his historical links with billionaire sex offender Jeffrey Epstein. The announcement was made in a separate statement alongside the UK high street bank’s annual results, which showed a profit before tax of £4.4bn for 2019, up 26% on the previous year. 

Futura Medical (LON:FUM) has commenced formal proceedings to get EU approval for its erectile disfunction gel formulation with full submission expected in mid-2020. A face-to-face meeting with the US regulator has also been confirmed for this quarter.

Clear Leisure (LON:CLP) says its legal position in the case against the former directors of Sipiem has been strengthened by a court ruling in Turin. The ruling confirmed Clear Leisure as Sipiem’s controlling owner and that its minority shareholder illegally tried to remove control of the company.

Britain is to clamp down on unregulated cannabis oil products. The Food Standards Agency says from March 2021 it will remove from sale unapproved CBD products.

Centrica’s retail businesses are getting better but progress is being slowed by its production businesses, which the British Gas Owner says are set for another tough year in 2020. Production write-offs meant a full year loss of £1.1bn

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharma CEO confident as he looks ahead to new Traumakine study

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen caught up with Proactive London's Andrew Scott soon after announcing they've amended the protocol for a second phase III study of its drug for acute respiratory distress syndrome (ARDS). The tweak's in response to...

2 days, 3 hours ago

RNS

Form 8.3 - ABBVIE INC - AMENDMENT

4 hours, 41 minutes ago

Form 8.3 - ALLERGAN PLC - AMENDMENT

4 hours, 42 minutes ago

FORM 8.3 - SOPHOS GROUP PLC

6 hours, 41 minutes ago

FORM 8.3 - SIRIUS MINERALS PLC

6 hours, 41 minutes ago

Form 8.3 - AMIGO HOLDINGS PLC

6 hours, 42 minutes ago

FORM 8.3 - ABBVIE INC

6 hours, 48 minutes ago

FORM 8.3 - ALLERGAN PLC

6 hours, 49 minutes ago

2 min read